P262 Guselkumab, an anti-interleukin-23p19 monoclonal antibody, in patients with active PsA who were biologic-naïve or prior TNFα inhibitor-treated: week 24 results of a Phase 3, randomised, double-blind, placebo-controlled study

Deodhar, A, Helliwell, P, Boehncke, W-H et al. (8 more authors) (2020) P262 Guselkumab, an anti-interleukin-23p19 monoclonal antibody, in patients with active PsA who were biologic-naïve or prior TNFα inhibitor-treated: week 24 results of a Phase 3, randomised, double-blind, placebo-controlled study. In: British Society for Rheumatology Annual Conference, 20-22 Apr 2020, Online.

Metadata

Authors/Creators:
  • Deodhar, A
  • Helliwell, P
  • Boehncke, W-H
  • Hsia, EC
  • Kollmeier, AP
  • Subramanian, RA
  • Xu, XL
  • Sheng, S
  • Zhou, B
  • Gorecki, PC
  • Ritchlin, C
Keywords: adrenal corticosteroids; antirheumatic drugs, disease-modifying; glucocorticoids; adultmonoclonal antibodies; anti-inflammatory agents, non-steroidal; disclosure; interleukins; prostate-specific antigen; psoriasis; randomization; safety; skin manifestations; immunoglobulin a; infections; mineralocorticoids; quality of life; enthesitis; frequency of responses; surrogate endpoints; sf-36; adverse event; physical function; dactylitis; apremilast; employee; guselkumab
Dates:
  • Published: April 2020
Institution: The University of Leeds
Academic Units: The University of Leeds > Faculty of Medicine and Health (Leeds) > School of Medicine (Leeds) > Institute of Rheumatology & Musculoskeletal Medicine (LIRMM) (Leeds) > Inflammatory Arthritis (Leeds)
Depositing User: Symplectic Publications
Date Deposited: 06 Nov 2020 15:36
Last Modified: 06 Nov 2020 15:36
Status: Published
Identification Number: https://doi.org/10.1093/rheumatology/keaa111.255
Related URLs:

Download not available

A full text copy of this item is not currently available from White Rose Research Online

Export

Statistics


CORE (COnnecting REpositories)